← Russell 3000 cross-section

IVVD Invivyd, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$265m
Revenue TTM
$58m
Net income TTM
$-107m
Free cash flow
$-110m
Composite score
Sector rank
#2739

Valuation

P / E
EV / EBITDA
EV / sales
1.8
FCF yield
-41.32%
Earnings yield vs 10-yr
-45.16pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-183.9%
EBITDA margin
ROE
-59.3%
ROIC
-535.9%
Revenue growth

Insider activity, last 90 days

Net open-market
$-0.18m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Since our inception and through June 30, 2026, we have financed our operations primarily through the sale and issuance of preferred and common stock, including net proceeds of $464.7 million from sales of our preferred stock, net proceeds of $327.5 million from sales of our common stock from our initial public offering (“IPO”), net proceeds of $92.1 million from sales of our common stock under the Sales Agreement (as defined below) and net proceeds of $181.6 million from sales of our common stock and pre-funded warrants under the Underwriting Agreements (as defined below). …Invivyd, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →